TGFB1 and Friedreich ataxia: Accordingly, TGFβ pathway inhibitors, targeting the TGFβ Receptor I (TGFβ RI), such as Galunisertib and LSN3301240, were initially tested for their ability to rescue hematopoiesis in FA models.